|
Market Closed -
Other stock markets
|
Pre-market 11:31:31 am | |||
| 271.00 EUR | +2.50% |
|
273.70 | +1.00% |
| 05/06 | Glenmark Pharmaceuticals Launches Generic Seizure Drug in US | MT |
| 04/06 | UCB and Biogen Inc. Demonstrate Clinical Profile of Dapirolizumab Pegol in Systemic Lupus Erythematosus At EULAR 2026 | CI |
Main competitors
| 1m. Revenue rev. | 4m. EPS revision | 4m. Revenue rev. | 1y. EPS revision | 1y. Revenue rev. | Visibility | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|
 | 19 | |||||||
| 28 | |||||||
| 23 | |||||||
| 16 | |||||||
| 30 | |||||||
| 23 | |||||||
| 20 | |||||||
| 26 | |||||||
| 12 | |||||||
| 23 | |||||||
| 21 | |||||||
| 5 | |||||||
| 26 | |||||||
| 9 | |||||||
| 12 | |||||||
| - | 1 | ||||||
| 10 | |||||||
| - | 1 | ||||||
| 2 | |||||||
| Average | 16 | |||||||
| Weighted average by Cap. | 20 |
- Stock Market
- Stocks
- UCB Stock
- Sector UCB
- Sector revisions
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition